Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

David C. Fajgenbaum(University of Pennsylvania), Éric Oksenhendler(Université Paris Cité), Simone Ferrero(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Raj Jayanthan(Baylor College of Medicine), Steve Schey(King's College London), Megan S. Lim(Memorial Sloan Kettering Cancer Center), Heather A. Leitch(University of British Columbia), Alexander Fosså(Oslo University Hospital), Raymond Wong(Chinese University of Hong Kong), Yasuharu Sato(Okayama University), Amy Chadburn(Cornell University), Gordan Srkalović(Regional Cancer Center), Mary Jo Lechowicz(Emory University), Sunita D. Nasta(University of Pennsylvania), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Adam Bagg(University of Pennsylvania), Frits van Rhee(Winthrop Rockefeller Foundation), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Sudipto Mukherjee(Cleveland Clinic), Christian Hoffmann(Hochschule für Angewandte Wissenschaften Kiel), Aaron M. Goodman(University of California San Diego), Angela Dispenzieri(Mayo Clinic), David Wu(University of Washington)
American Journal of Hematology
September 16, 2020
Cited by 32


Related Papers